<DOC>
	<DOCNO>NCT02229682</DOCNO>
	<brief_summary>This study make sure whether reduced-dose radiation treatment sufficient control disease patient early-staged extranodal nasal-type NK/T-cell lymphoma , get complete remission tumor chemotherapy new effective asparaginase-based GELOX regimen</brief_summary>
	<brief_title>Mild-dose IMRT Early-staged Extranodal Nasal-type NK/T-cell Lymphoma With CR Tumor After GELOX Chemotherapy</brief_title>
	<detailed_description>Definitive radiotherapy ( RT ) mainstay combined-modality treatment patient early-staged extranodal nasal-type NK/T-cell lymphoma ( ENKTL ) , use upfront short course chemotherapy . The typical dose RT recommend 50-56Gy conventional fractionation 3 dimensional conformal RT intensity-modulated radiation treatment ( IMRT ) . Asparaginase-based chemotherapy regimen investigate , primary result show superior previous anthracycline-based ( eg . CHOP ) chemotherapy . GELOX new asparaginase-based chemotherapy regimen design publish institute , rate complete remission ( CR ) well improve . We hypothesis reduced-dose radiation treatment ( IMRT 46Gy ) sufficient control disease patient early-staged ENKTL , get CR GELOX chemotherapy , validate phase II study . 1 . Patients : - All patient sign write informed consent form enrollment , study approve Sun Yat-sen University Cancer Center Ethics Board . - Baseline patient : Computed tomography ( CT ) scan chest , abdomen , pelvis , magnetic resonance image study head neck , bilateral bone marrow aspiration biopsy . Positron emission tomography-CT scan ( optional ) . Epstein-Barr virus ( EBV ) DNA blood level , titer EBV antibody ( EA-IgA , VCA-IgA ) . - Recheck GELOX chemotherapy IMRT : Epstein-Barr virus ( EBV ) DNA blood level , titer EBV antibody ( EA-IgA , VCA-IgA ) , compute tomography ( CT ) scan chest , abdomen , pelvis , magnetic resonance image study head neck , positron emission tomography-CT scan ( optional ) . 2 . Treatment Protocol : 1 . The GELOX regimen consist follow drug : gemcitabine：1250 mg/ m2 day 1 , iv drip ; oxaliplatin：85 mg/m2 day 1 , iv drip ; pegaspargase : 2500 IU/m 2 daily day 1 , intramuscular . The treatment cycle repeat every 14 day . 2 . IMRT deliver use 6-8MeV linear accelerator use extend involved-field intensity-modulated radiation treatment planning . The RT dose 46.2 gray ( Gy ) 22 fraction , simultaneous-boost method use . - We assign gross tumor volume ( GTV ) 46.2Gy/22F , delineate accord initial gross tumor volume identify image physical examination , include primary tumor involve regional lymph node . - The high-risk clinical target volume ( CTV1 ) assign 41.8Gy/22F , delineate include first batch adjacent structure around GTV , lymph node group apt involvement accord clinical feature individual tumor . - The low-risk clinical target volume ( CTV2 ) assign 36.3Gy/22F , delineate include extrapolated structure outside CTV1 site , LN group adjacent CTV1 LN group .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Lymphoma , T-Cell</mesh_term>
	<mesh_term>Lymphoma , Extranodal NK-T-Cell</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Asparaginase</mesh_term>
	<criteria>newly diagnose ENKTL age:1875years Ann Arbor stage IE , stage IIE cervical lymph node involvement lease one measurable lesion receive GELOX chemotherapy get CR radiotherapy Eastern CooperativeOncology Group performance status 0 2 Adequate hematologic function ( eg , white blood cell ≥ 3×10e9/l , neutrophil count ≥1.5×10e9/L , platelet count≥ 100×10e9/L ) , renal function ( eg , serum creatinine≤1.5 mg/dL creatinine clearance ≥50 mL minute ) , hepatic function ( e.g , total bilirubin≤ 2 time upper limit normal aspartate alanine transaminase level ≤ 3 time upper limit normal ) mismatch inclusion criterion , get nonCR GELOX chemotherapy IMRT , systematic central nervous system involvement , previous concomitant malignancy coexist medical problem could cause poor compliance study protocol , primary lesion upper aerodigestive tract</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>extranodal NK/T-cell lymphoma , nasal-type ,</keyword>
	<keyword>radiotherapy ,</keyword>
	<keyword>intensity-modulated radiation treatment ,</keyword>
	<keyword>asparaginase-based chemotherapy ,</keyword>
	<keyword>loco-regional control ,</keyword>
	<keyword>survival</keyword>
</DOC>